Relvar Ellipta

Per 100/25 mcg inhalation Predispensed fluticasone furoate 100 mcg, vilanterol trifenatate 25 mcg (delivered dose of fluticasone furoate 92 mcg, vilanterol trifenatate 22 mcg). Per 200/25 mcg inhalation Predispensed fluticasone furoate 200 mcg, vilanterol trifenatate 25 mcg (delivered dose of fluticasone furoate 184 mcg, vilanterol trifenatate 22 mcg)

Regular treatment of asthma in adults & adolescents ≥12 yr not adequately controlled w/ inhaled corticosteroid & "as needed" inhaled short-acting β₂-agonist. 100/25 mcg inhalation: Symptomatic treatment of adults w/ COPD w/ FEV₁ <70% predicted normal w/ an exacerbation history despite regular bronchodilator therapy.

Asthma Adult & adolescent ≥12 yr 1 inhalation of 100/25 mcg once daily, may be increased up to max: 200/25 mcg once daily. COPD Adult ≥18 yr 1 inhalation of 100/25 mcg once daily. Moderate or severe hepatic impairment Max: 100/25 mcg once daily.

Hypersensitivity.

Discontinue use if paradoxical bronchospasm occurs. Not to be used in symptomatic treatment of acute asthma or acute COPD exacerbation. Severe CV disease or heart rhythm abnormalities, thyrotoxicosis, uncorrected hypokalaemia or patients predisposed to low serum K levels. Cushing's syndrome, Cushingoid features, adrenal suppression, decreased bone mineral density, cataract, glaucoma, central serous chorioretinopathy, psychomotor hyperactivity, sleep disorders, anxiety, depression or aggression; pulmonary TB or patients w/ chronic or untreated infections. Pneumonia in patients w/ COPD or asthma. History of DM. High-dose & long-term use. Concomitant use w/ β-blockers, P-gp & CYP3A4 (eg, ketoconazole, ritonavir) inhibitors or sympathomimetic drugs. Not to be taken by patients w/ galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption. Hepatic impairment. Pregnancy & lactation. Growth retardation in childn & adolescents. Childn <12 yr. 200/25 mcg inhalation: Not to be used in patients w/ COPD.

Headache; nasopharyngitis. Pneumonia, URTI, bronchitis, flu, mouth & throat candidiasis; oropharyngeal pain, sinusitis, pharyngitis, rhinitis, cough, dysphonia; abdominal pain; arthralgia, back pain, fractures, muscle spasms; pyrexia.

Weakened or antagonized effect by β-blockers. Increased systemic exposure w/ CYP3A4 inhibitors eg, ketoconazole, ritonavir. Potentiated AR w/ other sympathomimetic drugs.

Antiasthmatic & COPD Preparations

R03AK10 - vilanterol and fluticasone furoate ; Belongs to the class of adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics. Used in the treatment of obstructive airway diseases.

B